Your browser doesn't support javascript.
loading
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
Ferrari, Filipe; Martins, Vítor Magnus; Fuchs, Flávio Danni; Stein, Ricardo.
  • Ferrari, Filipe; Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul. Programa de Pos-Graduacao em Cardiologia e Ciencias Cardiovasculares. Porto Alegre. BR
  • Martins, Vítor Magnus; Hospital de Clinicas de Porto Alegre. Porto Alegre. BR
  • Fuchs, Flávio Danni; Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul. Programa de Pos-Graduacao em Cardiologia e Ciencias Cardiovasculares. Porto Alegre. BR
  • Stein, Ricardo; Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul. Programa de Pos-Graduacao em Cardiologia e Ciencias Cardiovasculares. Porto Alegre. BR
Clinics ; 76: e2342, 2021. tab, graf
Article in English | LILACS | ID: biblio-1286087
ABSTRACT
Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19) pandemic, a research letter published in The Lancet implicated drugs that antagonize the renin-angiotensin-aldosterone system (RAAS) in an unfavorable prognosis of COVID-19. This report prompted investigations to identify mechanisms by which blocking angiotensin-converting enzyme 2 (ACE2) could lead to serious consequences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The possible association between RAAS inhibitors use and unfavorable prognosis in this disease may have been biased by the presence of underlying cardiovascular diseases. As the number of COVID-19 cases has increased worldwide, it has now become possible to investigate the association between RAAS inhibitors and unfavorable prognosis in larger cohorts. Observational studies and one randomized clinical trial failed to identify any consistent association between the use of these drugs and unfavorable prognosis in COVID-19. In view of the accumulated clinical evidence, several scientific societies recommend that treatment with RAAS inhibitors should not be discontinued in patients diagnosed with COVID-19 (unless contraindicated). This recommendation should be followed by clinicians and patients.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Coronavirus / COVID-19 Type of study: Controlled clinical trial / Practice guideline / Observational study Limits: Humans Language: English Journal: Clinics Journal subject: Medicine Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital de Clinicas de Porto Alegre/BR / Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Coronavirus / COVID-19 Type of study: Controlled clinical trial / Practice guideline / Observational study Limits: Humans Language: English Journal: Clinics Journal subject: Medicine Year: 2021 Type: Article Affiliation country: Brazil Institution/Affiliation country: Hospital de Clinicas de Porto Alegre/BR / Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul/BR